Researchers investigated the antileukemic activity and underlying molecular mechanism of the combination of ONC213 + venetoclax against AML cells. They reported that ONC213 could resensitize venetoclax + azacitidine-resistant AML cells to venetoclax therapy and target leukemia stem cells ex vivo and in vivo.
[Journal of Experimental & Clinical Cancer Research]